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Abstract
Aim—Since whole-genome sequencing (WGS) information can have positive and negative 
personal utility for individuals, we examined predictors of willingness to pay (WTP) for WGS.
Patients & methods—We surveyed two independent populations: adult patients (n = 203) and 
college seniors (n = 980). Ordinal logistic regression models were used to characterize the 
relationship between predictors and WTP.
Results—Sex, age, education, income, genomic knowledge and knowing someone who had 
genetic testing or having had genetic testing done personally were associated with significantly 
higher WTP for WGS. After controlling for income and education, males were willing to pay 
more for WGS than females.
Conclusion—Differences in WTP may impact equity, coverage, affordability and access, and 
should be anticipated by public dialog about related health policy.
Keywords
access to healthcare; attitude to health; healthcare costs; human genome; personalized medicine; 
whole genome sequencing; willingness-to-pay
Whole-genome sequencing (WGS) involves sequencing nearly all of an individual’s genome 
and has multiple applications, ranging from disease screening to treatment planning and 
pharmacogenomic uses [1–5], ultimately aimed at improving patient outcomes. As WGS 
techniques continue to improve and the associated costs decline [6], it is possible that the use 
of WGS will become more widely adopted and integrated into routine clinical practice. 
WGS results can include: clinically actionable findings (treatable or preventable), findings 
that are not currently clinically actionable (with unclear treatment implications) and findings 
of uncertain significance [7]. Further, the findings can be divided into primary findings 
(variants in genes relevant to the diagnostic indication for which sequencing was ordered) 
and secondary findings (also termed incidental findings; variants in genes not relevant to a 
diagnostic indication for which sequencing was ordered) [8]. The volume and complexity of 
WGS information has both positive and negative consequences depending on individual 
preferences and values. WGS can also reveal pharmacogenomic findings that may be of 
clinical value, depending on the genes included in the panel and corresponding drug and 
clinical indication.
One approach to assessing the value of personalized medicine technologies such as WGS is 
to determine how much people are willing to give up monetarily for both health and 
nonhealth benefits associated with testing and treatment, estimated as ‘willingness to pay 
(WTP)’ [9]. WTP reflects the personal utility, or disutility where there are negative 
consequences. A recent nationally representative US survey found that more than half of 
those queried would not pay more than US$500 for actionable WGS information and one 
third would not pay more than US$200 for nonactionable information [10]. Marshall et al. 
also found that WGS information had a positive value for some but negative value for others, 
suggesting the importance of preferences to inform access and funding policies about WGS 
testing and reporting as an example of personalized medicine [10].
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In addition to assessing the value of personalized medicine technologies, it is important to 
consider how the younger generation values these technologies as they are the future 
generation who are likely to be using them. In this paper, we report on the WTP for WGS 
from independent surveys of two different adult populations (middle-aged individuals and 
college seniors). We compare these two different populations to understand how differences 
in age, life stage and life experience impact value and access.
Patients & methods
The MedSeq Project: primary care & cardiology participants
The MedSeq Project (Brigham and Women’s Hospital at Harvard Medical School and 
Baylor College of Medicine), protocol published elsewhere [11], surveyed two adult 
populations: patients deemed generally healthy by their primary care physicians from 
primary care practices (40–65 years old) and patients with hypertrophic or dilated 
cardiomyopathy from cardiology practices (18 years and older). Participants were recruited 
by their physicians, who were also study participants, and randomized to standard of care, 
including a detailed review of their family history, or standard of care plus family history 
and an interpreted WGS examining over 4600 disease-associated genes. Participants 
completed surveys (electronically or pen and paper) after study enrollment (baseline) and 
after disclosure of study results, and were followed for 6 months to explore the impact of 
WGS on their health, healthcare utilization, emotional reactions and attitudes. This paper 
reports on the WTP questions for the 203 participants who completed the baseline survey 
prior to learning their randomization status and who responded to any of the WTP items.
Participants were directly asked about their WTP for WGS as follows:
• If you could receive this WGS test outside of this study, how likely would you be 
to ask for this test if:
– Your health insurance covered the cost of testing (Likert scale response 
options: definitely not to definitely would have testing).
– You had to pay for the testing yourself (Likert scale response options: 
definitely not to definitely would have testing).
• How much would you be willing to pay for this WGS test if you were not in this 
study and it was not covered by your insurance? (Free text: US dollars, measured 
as a continuous variable).
The baseline survey also assessed genomic knowledge using an existing scale (modified 
with permission from Likert to true/false response options) [12]. Demographic information, 
including age, sex, education level, ethnicity, annual household income and health status 
were collected.
College seniors
In a separate effort, senior college students (18 years or older) from University of California 
(UC) Berkeley and San Francisco State University, approximately 5500 and 2000, 
respectively, were invited to participate in an anonymous survey to investigate issues related 
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to genetic testing. The main difference between the surveyed populations was that UC 
Berkeley students had previously participated in a program which explored the theme of 
genetics and personalized medicine which is described elsewhere [13]. A total of n = 980 
students from both universities completed the survey and were included in the final analyses.
Surveys were administered electronically and participants provided informed consent before 
answering any questions. Students who completed the survey were entered into an optional 
random drawing for an iPad and/or no-cost dinner with UC Berkeley professors at a local 
restaurant.
Participants were asked about their willingness to have their whole genome sequenced, and 
their WTP (in US dollars) based on the following scenario and questions:
• In the very near future, an individual will be able to have his/her whole-genome 
(DNA) sequenced in order to understand his/her entire genetic makeup. The test 
results each individual receives when his/her whole genome is sequenced will be 
a MIXTURE of:
– Results for which important medical or other health related decisions 
CAN be made;
– Results for which medical or other health related decisions CANNOT 
be made because they are unlikely to be useful for preventing or 
treating a condition BUT the results may still be of PERSONAL 
INTEREST;
– Results of UNKNOWN importance.
• Experts such as clinicians and scientists determine what findings from WGS can 
be used to help treat or prevent a disease.
Based on the information provided, how likely are you to have your whole genome 
sequenced? (Likert scale response options: very unlikely to very likely to have whole 
genome sequenced).
Based on the information provided, how much would you be willing to pay out of pocket for 
WGS? (response options: US$0–200, US$200–500, US$500–1000, US$1000–3000, >US
$3000).
The survey also included a component that assessed genomic knowledge using an existing 
survey instrument [14]. Demographic information, including age, sex, parent’s education 
level, race/ethnicity, annual family household income and health status were collected.
Statistical methods
Descriptive statistics were calculated for the demographic variables. Although race/ethnicity 
were specified by respondents using multiple categories, in order to compare the two 
populations, we dichotomized race/ethnicity to non-Hispanic white or not. Categorical 
distributions of WTP and willingness to have WGS were calculated for the college seniors 
study participants. Mean WTP was calculated for the MedSeq Project participants.
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Predictors of WTP identified using ordinal logistic regression for both populations. We 
identified a priori common variables to each dataset that we anticipated might be predictors 
of WTP for WGS. Categories used for the WTP outcome variable in the ordinal logistic 
regression analysis were: ≤US$199, US$200–499 and ≥US$500. Regression parameter 
estimates, standard errors (SEs) and p-values were reported for each predictor in all models. 
Analyses were conducted using IBM SPSS Statistics (version 24.0) and STATA (version 
13.1). Results with p-values < 0.05 were considered statistically significant.
Results
The MedSeq Project: primary care & cardiology patients
Overall, mean age of participants (n = 203) was 55 years (standard deviation [SD]: 11.3) 
(Table 1). Participants were predominantly non-Hispanic white (88%, n = 177), the majority 
reported having a college degree (81%, n = 165) and an annual household income of US
$100,000 or greater (61%, n = 124). In addition to reporting high levels of education, 
participants demonstrated strong genomic knowledge. The mean genomic knowledge score 
for participants at baseline was 10 out of 11 (91%) correct items and there were no 
significant differences in knowledge between primary care and cardiology participants. 
Some participants (n = 30) did not answer the WTP questions, but there were no significant 
demographic differences between those who responded and those who did not (p > 0.05).
The majority of MedSeq Project participants (63%, n = 127 out of n = 201 respondents that 
answered the question) responded that they would definitely have testing if the cost were 
covered by their insurance. Participants were split on whether they would have testing if they 
had to self-pay, with 48% (n = 95 out of n = 200 respondents that answered the question) 
responding that they would probably not have testing and 31% (n = 62 out of n = 200 
respondents that answered the question) responding that they probably would have testing. 
On average MedSeq Project participants were willing to pay US$1035 (SD: US$1707). 
Figure 1 summarizes the distribution of amounts that MedSeq Project respondents were 
willing to pay for WGS (n = 174).
We found that sex, education, age and genomic knowledge were associated with 
significantly higher WTP (Table 2). Males were willing to pay more than females (p = 
0.022), college graduates were willing to pay more than noncollege graduates (p = 0.045), 
and individuals 66 years of age and older were willing to pay more than those between 51–
65 years and those 50 years of age and younger (p = 0.042 and p = 0.013, respectively). 
Those with better genomic knowledge were also willing to pay more (p = 0.035).
College seniors
Overall, most respondents were younger than 29 years (n = 946, 96%), with nearly half 
being 21 years and younger (Table 1). 38% (n = 372) of respondents reported being non-
Hispanic white, having parents who are college graduates or have more than a college 
degree/diploma (62%, n = 606) and 39% (n = 385) reported annual family household income 
of US$100,000 or greater. The mean proportion of correct genomic knowledge questions 
was 85% (Table 1).
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With regard to genetic awareness, 47% (n = 459) indicated they strongly agreed or agreed 
they were aware of genetic testing options for health and personalized medicine. When it 
came to interest in having genetic testing, 33% (n = 320) indicated they were neutral and 
49% (n = 481) indicated they strongly agreed or agreed. When asked about pursuing genetic 
testing for themselves, 14% (n = 132) indicated they were not interested. When asked about 
likelihood of having their whole genome sequenced based on the scenario provided, more 
than half of respondents (59%, n = 578) indicated they were neutral to likely (data not 
shown).
When asked about how much they would be willing to pay out of pocket for WGS, the 
majority of respondents (69%, n = 672) indicated they would not be willing to pay more 
than $500. Figure 2 summarizes the distribution of amounts that college seniors were willing 
to pay for WGS (n = 785). We found that sex, annual family household income and knowing 
someone who had genetic testing or having had genetic testing done personally were 
associated with significantly higher WTP (Table 2). Males were willing to pay more than 
females (p = 0.039), individuals who reported a family household income of US$100,000 or 
more were willing to pay more than those who reported a family household income of less 
than US$100,000 (p < 0.001), and those who knew someone who had genetic testing or had 
it done personally were willing to pay more than those who did or had not (p = 0.019). The 
college that respondents attended was not a significant predictor of WTP (p = 0.65).
Discussion
On average, MedSeq Project participants were willing to pay US$1035 for WGS and in 
contrast, the majority of college seniors were not willing to pay more than US$500 for 
WGS. We found that various demographic characteristics including male, older age, higher 
education, higher family household income, better genomic knowledge and knowing 
someone who had genetic testing or having had genetic testing done personally were 
associated with a significantly higher WTP for WGS. Furthermore, even after controlling for 
education, income, age, genetic knowledge or experience with testing, males were willing to 
pay significantly more for WGS than females. Our observations around demographics are 
consistent with associations that have been observed with WTP around other health 
interventions [15]. However, in addition to the demographic factors, we found that better 
genomic knowledge and knowing someone who had genetic testing or having had genetic 
testing done personally is independently associated with significantly higher WTP. Our 
study explores differences in WTP for WGS between two populations that differed by age 
(college seniors population mostly younger than 29 years, compared with MedSeq Project 
population with a mean age of 55 years), life stage and life experience, which to our 
knowledge has not been explored in other research (Supplementary Online Table). This 
makes it challenging to directly compare these two populations, but also reflects a wide 
range of circumstances in the populations we have examined.
Other surveys in general population samples have explored individual knowledge, attitudes 
towards genetic testing and preferences for the receipt of genetic information, finding that 
men and women may differ in their views. One study of a representative sample of US adults 
revealed that males were more likely to have heard of personalized medicine [16]. In 
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contrast, a Dutch survey showed that women had significantly more knowledge about 
genetic tests and were more likely to have had an assessment of family history to identify 
risks associated with hereditary conditions and risk assessment practices [17]. A recent 
systematic review showed mixed evidence for sex differences in attitudes and preferences 
toward genetic testing in relation to obesity, diabetes and heart disease [18]. Results from 
another systematic review suggested that women viewed genomic tests less positively than 
men and were less likely to pursue direct-to-consumer testing [19].
In summarizing key studies that estimated WTP for genetic/genomic testing (see 
Supplementary Online Table, which takes data from [20–32]), we found that individuals 
from the general population would be interested in genetic testing if free of charge [20,25–
26], and most studies have found that few people are willing to pay more than $500 [20,25–
28,32]. WTP is influenced by age, with younger individuals willing to pay more than older 
individuals [25]. These findings are consistent with the WTP estimates from our college 
seniors participants; however, our MedSeq Project participants were willing to pay more 
than US$500. The higher WTP estimates of MedSeq Project participants were made prior to 
learning their randomization status and probably reflects a combination of their older age, 
high income, high level of genetic knowledge and the enthusiasm for genetic testing that 
prompted them to voluntarily enroll in this trial of WGS.
In contrast to surveys within the general population, surveys of individuals with specific 
diseases (or of those at risk for specific diseases) revealed that these individuals are willing 
to pay for genetic testing that identifies benefit from treatment, changes in treatment or level 
of risk and is influenced by household income (those with higher income willing to pay 
more) and understanding of genetic information (Supplementary Online Table) [27,29–31]. 
Research by Eden et al. and Cuffe et al. found that prior knowledge or a better understanding 
of the condition or genetic testing led to higher WTP [27,29]. Concern about disease may 
also play an important role. Graves et al. reported that women with less understanding of 
genetic testing but more cancer worry were willing to pay more [30]. Similar to the findings 
with the general population, there is a wide range of estimates of what patients are willing to 
pay for genetic testing (US$100–13,000 but most less than US$2000). It is important to note 
that these studies tend to explore how genetic testing can inform or change treatment. These 
findings align more closely with the WTP estimate from our MedSeq Project participants.
Our results must be considered in light of certain limitations. One potential study limitation 
is that our populations are not representative of the general population in terms of 
sociodemographic factors. Another limitation is participation bias whereby those who were 
more interested in genetic testing might have been more likely to participate in each study 
than those who were not interested in the topic. The MedSeq Project population is highly 
knowledgeable about genomic concepts, well-educated and relatively affluent, and was also 
highly self-selected in that they had each agreed to participate in a sequencing study prior to 
being queried. The college seniors population included two different public university 
student populations, with an unequal number of participants from each. The San Francisco 
State University and UC Berkeley student populations in the current study shared important 
demographic similarities including sex distribution, average age, life stage and average 
personal education level; some differences were present including family household income 
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and parental education level (data not shown). This combined population may not reflect the 
opinions of college students in general or the general population; however, it is important to 
note each student sample was similar to the overall demographic distribution of students 
from which it was drawn (data not shown).
Another potential limitation specific to the MedSeq Project population is that WTP was 
assessed prior to learning their randomization status or receiving WGS results, for those 
randomized to receive it. Receiving WGS information could impact one’s WTP. Further, 
both populations were assessing hypothetical WTP, which does not always reflect actual 
practice.
Additional research in larger, more diverse populations will be necessary to inform the 
future of genomics practice. Findings about WTP such as ours could be used to estimate the 
potential expected uptake of these personalized medicine technologies, and also to compare 
with observed rates of uptake in routine clinical practice over time.
Conclusion
As WGS becomes more available, these findings raise questions about access, coverage, 
affordability and the adoption of this personalized medicine technology into routine clinical 
practice. Differences in WTP in subgroups of individuals suggests that some individuals 
may end up with limitations on their access to WGS, which could lead to potential 
disparities. This type of heterogeneity, particularly by age, sex, life stage and life experience, 
is also important since the younger, more tech-savvy individuals are likely to be using these 
technologies in the future.
Our findings suggest WTP between US$0 and US$1000, coming close to the lower current 
cost of clinical WGS, which can range from US$1000 to US$15,000 [33]. Given the 
variation in coverage depending on insurance company, policies and type of testing [33], this 
raises concerns about access to WGS, especially for those who may not have insurance 
coverage. Policies on coverage and reimbursement for WGS, and personalized medicine 
more broadly, should be informed by public dialog and population preferences that consider 
the implications of access and equity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Executive summary
• As whole genome-sequencing (WGS) techniques continue to improve and the 
associated costs decline, the use of WGS may become more widely adopted 
and integrated into routine clinical practice.
• The volume and complexity of WGS information has both positive and 
negative consequences depending on individual preferences and values.
• It is important to consider how the younger generation values these 
technologies as they are the future generation who are likely to be using them, 
which raises questions about how differences in age, life stage and life 
experience impact value and access.
• Whether WGS can achieve its potential to improve patient outcomes will 
depend on what information is given to patients, and how patients and 
providers respond to and value the information provided.
• Various demographic characteristics including male, older age, higher 
education, higher family household income, better genomic knowledge and 
knowing someone who had genetic testing or having had genetic testing done 
personally were associated with a significantly higher willingness to pay for 
WGS.
• Our findings suggest willingness to pay between US$0 and US$1000, which 
is approaching the current cost of clinical WGS, which can range from US
$1000 to US$15,000.
• Policies on coverage and reimbursement for WGS, and personalized medicine 
more broadly, should be informed by public dialog and population 
preferences that consider the implications of access and equity.
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Figure 1. Distribution of willingness to pay for the MedSeq Project (n = 174)
WGS: Whole-genome sequencing.
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Figure 2. Distribution of willingness to pay for college seniors (n = 785)
WGS: Whole-genome sequencing.
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Table 1
Demographics for the MedSeq Project and college seniors.
Characteristic The MedSeq Project (n = 203) College seniors (n = 980)†
Age (years):
 Mean (SD) 55 (11.3) –
 ≤21 – 475 (48)
 22–29 n/a 471 (48)
 ≥30 n/a 23 (2)
 ≤50 64 (32) n/a
 51–65 106 (52) n/a
 ≥66 33 (16) n/a
Sex, n (%):
 Male 101 (50) 314 (32)
 Female 102 (50) 647 (66)
Personal education level (MedSeq) and parent’s education level (college 
seniors), n (%):
 No college degree 38 (19) 342 (35)
 College degree 165 (81) 606 (62)
Annual household income, n (%)‡:
 <US$100,000 71 (35) 475 (48)
 ≥US$100,000 124 (61) 385 (39)
Race/ethnicity, n (%):
 Non-Hispanic white 177 (88) 372 (38)
Reported previous genetic testing, n (%):
 No 144 (71) n/a
 Yes 59 (29) n/a
Know someone who had genetic testing/had genetic testing done personally, n 
(%):
 No n/a 265 (27)
 Yes n/a 453 (46)
Mean genomic knowledge score (SD)§ 10 (1.2) n/a
Mean proportion of correct genomic knowledge questions, % (SD)¶ n/a 85 (9.7)
†
May not total 100% due to missing data.
‡
The MedSeq Project reports annual household income and college seniors reports annual family household income.
§
Mean genomic knowledge score ranged from 0 to 11, with 11 representing high genomic knowledge.
¶
Mean proportion of correct genomic knowledge questions ranged from 0 to 100%, with 100% representing 16 out of 16 genomic knowledge 
questions answered correctly.
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n/a: Not applicable and did not include this variable due to reporting differences between the two studies; SD: Standard deviation.
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Table 2
Ordinal logistic regression parameter estimates for predictors of willingness to pay for the MedSeq Project (n 
= 168) and college seniors (n = 782).
Variables MedSeq Project, parameter 
estimate (SE)
College seniors, parameter 
estimate (SE)
Age (years):
 ≤21 n/a† – ‡
 22–29 n/a† 0.09 (0.15)
 ≥30 n/a† 0.10 (0.53)
 ≤50
−1.54 (0.62)* n/a†
 51–65
−1.25 (0.61)* n/a†
 ≥66
–
‡ n/a†
Female
−0.76 (0.33)* −0.32 (0.15)*
College degree 0.87 (0.44)* 0.04 (0.18)
Annual household income ≥US$100,000§ 0.44 (0.37) 0.62 (0.17)**
No previous genetic testing −0.06 (0.37) n/a†
Know someone who had genetic testing/had genetic testing 
done personally
n/a† 0.40 (0.17)*
Genomic knowledge score (MedSeq) and mean proportion of 
correct genomic knowledge questions (college seniors) 0.31 (0.15)
* −0.01 (0.01)
Parameter estimate corresponds to an increase or decrease (depending on direction of effect) in the log odds of being in a higher level of 
willingness to pay. For example, a one unit increase in female (i.e., going from 0 to 1, or male to female) corresponds to a 0.76 decrease in the log 
odds of being in a higher level of willingness to pay for MedSeq, and 0.32 decrease in the log odds of being in a higher level of willingness to pay 
for college seniors, given all the other variables in the model are accounted for (held constant). Willingness to pay categories used in the ordinal 
logistic regression analyses were ≤US$199, US$200–499 and ≥US$500.
†
This variable was not included in model due to reporting differences between the two studies.
‡
Reference group
§
The MedSeq Project explored annual household income, college seniors explored annual family household income.
*p < 0.05.
**p < 0.01.
n/a: Not applicable; SE: Standard error.
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